Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JP8D
|
|||
| Former ID |
DNCL001876
|
|||
| Drug Name |
GSK249320
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Stroke [ICD-11: 8B20; ICD-10: I64] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myelin-associated glycoprotein (MAG) | Target Info | . | [2] |
| Pathway Interaction Database | p75(NTR)-mediated signaling | |||
| WikiPathways | Spinal Cord Injury | |||
| Glial Cell Differentiation | ||||
| Signalling by NGF | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01808261) POC in Patients With Ischaemic Stroke. U.S. National Institutes of Health. | |||
| REF 2 | First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.